logo-loader
viewMaxCyte Inc

MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering

Cell being injected
Flow Electroporation is used in gene editing and allows almost any molecule to be delivered into a cell

MaxCyte Inc (LON:MXCT) has signed a research agreement with Kite Pharma Inc, a subsidiary of US drugmaker Gilead Sciences Inc (NASDAQ:GILD), to use its Flow Electroporation Technology (FET) platform.

The AIM-listed bioscience firm said under the agreement Kite would use the FET platform to enable non-viral cell engineering.

WATCH: Major announcements for MaxCyte

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

Doug Doerfler, president and chief executive of MaxCyte, said Kite would be utilising the firm’s platform to enable gene-editing technologies for the research and development of new therapeutics.

The deal follows a commercial license agreement signed last week between MaxCyte and gene-based medicine maker CRISPR Therapeutics in a move to advance the development of anti-cancer treatments.

Quick facts: MaxCyte Inc

Price: 110 GBX

AIM:MXCT
Market: AIM
Market Cap: £63.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read